Biologics and biosimilars are reshaping cancer treatment, but ensuring their safety and efficacy remains a complex challenge. Our oncology roundtable report brings together experts from Cerba Research, Sanofi, NexImmune, Merck, and Daiichi Sankyo to explore the latest advancements in immunogenicity testing, regulatory considerations, and emerging technologies driving oncology drug development.

Gain valuable insights on streamlining assay selection, bridging immunogenicity studies from preclinical to clinical stages, and leveraging AI-driven approaches in bioanalysis. Stay ahead of the rapidly changing industry standards so you can make informed decisions for your drug development pipeline.